Evidence map›Paper›PMID 32079623›Full record

ArticleESMO open2020

Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study.

David Lau, Eleftheria Kalaitzaki, David N Church, Hardev Pandha, Ian Tomlinson, Nicola Annels, Marco Gerlinger, Francesco Sclafani, Gillian Smith, Ruwaida Begum and 7 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03827044 (POLEM), which is not on this map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03827044 phase3terminatednot on this map

POLEM:Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Exonuclease Domain Mutant Colon Cancer: A Phase 3 Randomised Study

TypeinterventionalSponsorRoyal Marsden NHS Foundation TrustRan2018 to 2022Enrolled30ConditionsPOLE Exonuclease Mutant Colon Cancer, Microsatellite Instability, Stage III Colon CancerArmsAvelumab
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. New insight in immunotherapy and combine therapy in colorectal cancer.Frontiers in cell and developmental biology · 2024
    Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Emerging evidence of immunotherapy for colorectal cancer.Annals of gastroenterological surgery · 2023
    Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

David LauRoyal Marsden Hospital NHS Foundation Trust, London, UK.ORCID 0000-0003-0447-3094
Eleftheria KalaitzakiRoyal Marsden Hospital NHS Foundation Trust, London, UK.
David N ChurchWellcome Centre for Human Genetics, University of Oxford, Oxford, Oxfordshire, UK.
Hardev PandhaUniversity of Surrey, Guildford, Surrey, UK.
Ian TomlinsonInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Nicola AnnelsUniversity of Surrey, Guildford, Surrey, UK.
Marco GerlingerInstitute of Cancer Research, London, UK.
Francesco SclafaniRoyal Marsden Hospital NHS Foundation Trust, London, UK.
Gillian SmithRoyal Marsden Hospital NHS Foundation Trust, London, UK.
Ruwaida BegumRoyal Marsden Hospital NHS Foundation Trust, London, UK.
Richard CruxRoyal Marsden Hospital NHS Foundation Trust, London, UK.
Angela GillbanksRoyal Marsden Hospital NHS Foundation Trust, London, UK.
Sarah WordsworthNuffield Department of Population Health, University of Oxford, Oxford, Oxfordshire, UK.
Ian ChauRoyal Marsden Hospital NHS Foundation Trust, London, UK.
Naureen StarlingRoyal Marsden Hospital NHS Foundation Trust, London, UK.
David CunninghamRoyal Marsden Hospital NHS Foundation Trust, London, UK.
Tony DhillonRoyal Surrey NHS Foundation Trust, Guildford, UK t.dhillon@surrey.ac.uk.

Funding

Cancer Research UK 18377Cancer Research UK 27963Cancer Research UK C26642/A27963
6 · The paper itself

Abstract

background10%-15% of early-stage colon cancers harbour either deficient mismatch repair (dMMR), microsatellite instability high (MSI-H) or

methodsWe are recruiting patients with completely resected, stage III colon cancer confirmed to have dMMR/MSI-H, locally or TRIAL REGISTRATION NUMBER: NCT03827044.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalClinical Trials, Phase III as TopicColonic NeoplasmsDNA Mismatch RepairExonucleasesFemaleHumansMaleMicrosatellite InstabilityNeoplasm StagingRandomized Controlled Trials as TopicAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalavelumabExonucleasesadjuvant therapycolon cancermicrosatellite instabilitymismatch repairPOLE mutation

Identifiers

PMID32079623
PMCPMC7046393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.